Abstract
In a clinical study phase II 2 x 200 mg tepoxalin were administered orally over 3.5 days to 7 patients with osteoarthritis (OA) and 6 patients with rheumatoid arthritis (RA). Leukotriene (LT) B4 and LTC4 release from blood was decreased, thromboxane (TX) B2 release was reduced significantly. Relevant concentrations of tepoxalin and its metabolite in plasma and synovial fluid were detectable. According to the visual analog scale, pain was reduced significantly for both groups. In RA patients, the Ritchie Index, the number of swollen joints, and morning stiffness were reduced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
